Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 (SLVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.07 (market cap $2.86B), while Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 trades at $61.01 (market cap $395.75M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 7.2× Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033's market cap, and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 is more actively traded (103,065 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033 for 65 Days on average.
| DYN | SLVO | |
|---|---|---|
Market Cap | $2.86B | $395.75M |
Volume | 3,341,579 | 103,065 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.78 | $107.41 |
52-Week Low | $14.60 | $60.11 |
Typical Hold Time | 0 Days | 65 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
SLVO is trading at $63.37, down 1.17% with bearish technical signals showing 16 sell indicators versus 1 buy. The stock recently crossed below its 50-day moving average of $73.20, indicating weakening momentum. Key support levels cluster around $62-63 while resistance sits at $64-65. Recent news highlights silver price declines affecting the ETN's performance.
The outlook remains cautious with technical indicators signaling bearish momentum and silver market volatility creating headwinds. Investment opportunity exists for contrarian investors if silver prices stabilize, but risks include continued commodity weakness and the ETN's structural complexities requiring careful evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Ubs Ag Etracs Silver Shares Covered Call ETN Exp 21 Apr 2033
SLVO is an exchange-traded note issued by UBS AG that provides investors with exposure to the performance of a silver-based covered call strategy. The ETN tracks the daily return of the ISE Enhanced 100x Leveraged Silver ETN Index, which combines a long position in silver with a covered call strategy on the silver position. This strategy aims to generate current income from the option premiums, which can provide a buffer during sideways or slightly down markets for silver, but it also caps the potential gains from a significant rise in silver prices. As an ETN, it is subject to the credit risk of the issuer, UBS AG, and has an expiration date of April 21, 2033.
Read more on SLVO →
